Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003

Gratwohl, Aloïs; Baldomero, Helen; Schmid, Olivier; Horisberger, Bruno; Bargetzi, Mario; Urbano-Ispizúa, Álvaro

doi:10.1038/sj.bmt.1705104

Cited by 88 publications

(70 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Still, it documents the change in stem cell source where now peripheral blood is the preferred source of choice for all situations, with the exception of bone marrow failure syndromes. 8,19,20 It is interesting that the proportion reaches similar values for The survey gives some generic information on the use of RIC HSCT. 9,10 About one-third of all allogeneic HSCT are RIC HSCT, the trend appears now stable with a similar proportion over the past 3 years.…”

Section: Discussionmentioning

confidence: 99%

EBMT activity survey 2004 and changes in disease indication over the past 15 years

Gratwohl

Baldomero

Frauendorfer

et al. 2006

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

This fifteenth annual European Group for Blood and Marrow Transplantation activity report lists the transplant activity in Europe in 2004 and documents the changes in indication over the past 15 years. In 2004, there were 22 216 first hematopoetic stem cells (HSCT), 7407 allogeneic (33%), 14 809 autologous (67%) and 4378 additional re-or multiple transplants reported from 592 centres in 38 European and five affiliated countries. Main indications were leukemias (7045 (32%; 78% allogeneic)); lymphomas (12 310 (55%; 94% autologous)); solid tumors (1759 (8%; 93% autologous)) and nonmalignant disorders (1015 (5%; 92% allogeneic)). In comparison, 145 teams from 20 countries performed 4234 HSCT (2137 allogeneic, 50%; 2097 autologous, 50%) in 1990. The overall increase was accompanied by major changes. Stem cell source changed from bone marrow to peripheral blood. More than one-third of allogeneic HSCT are now from unrelated donors. Reduced intensity conditioning is employed for one-third of allogeneic HSCT. Leukemias for allogeneic and lymphoproliferative disorders for autologous HSCT continue to increase. The decline in HSCT for chronic myeloid leukemia appears to level off for the first time since 1999. These data are informative for patient counselling and decision making for health care professionals. Bone Marrow Transplantation (2006) 37, 1069-1085. doi:10.1038/sj.bmt.1705377 Keywords: hematopoietic stem cell transplantation; Europe; transplant rates; leukemia; solid tumor; nonmalignant diseases IntroductionTransplantation of hematopoietic stem cells (HSCT) offers a unique opportunity for long-term disease control to many patients with severe malignant or hematopoietic stem cells malignant, acquired or congenital disorders of the hematopoietic system or with chemo-radiosensitive tumors. [1][2][3] HSC has seen rapid expansion over the last decade and the increasing demand for this high-cost procedure can present a challenge for health care systems in any country. Precise information on current use and trends is essential for patients, physicians and health care providers alike. 4,5 The activity survey of the European Group for Blood and Marrow Transplantation (EBMT) was designed in 1990 to provide this information in a most efficient way and to disseminate it rapidly on an annual basis. 6 All EBMT members and affiliated teams, known to perform transplants, were requested to report their numbers of patients transplanted by indication, stem cell source and donor type on an annual basis. The initial survey sheet was slightly changed over the years, to respond to changes in indication and to collect additional generic information on the numbers of re-or multiple transplants, on the percentage of cord blood HSCT and on the percentage of transplants with reduced intensity conditioning (RIC HSCT). The EBMT survey was adopted by the General Assembly as a mandatory self-reporting system. It forms now an integral part of a comprehensive quality assurance program JACIE (Joint Accreditation Committee of the International Socie...

show abstract

Section: Discussionmentioning

confidence: 99%

EBMT activity survey 2004 and changes in disease indication over the past 15 years

Gratwohl

Baldomero

Frauendorfer

et al. 2006

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

show abstract

“…16 Mobilization of HPCs in patients with malignancies is a routine practice in highdose therapy and auto-SCT. 17 The factors predicting the magnitude of HPC mobilization have been well documented. [18][19][20] The mobilizing regimen usually consists of CY of 3-7 g/m 2 or disease-specific agents.…”

Section: Discussionmentioning

confidence: 99%

Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs

Ria

Gasparre

Mangialardi

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…This increase is most pronounced for patients with acute leukemias and is observed for related and unrelated HSCT as well. 6 The survey points as well to the differences in transplant rates. The factors for these differences were shown here and in a previous report.…”

Section: Discussionmentioning

confidence: 99%

Why are there regional differences in stem cell transplantation activity? An EBMT analysis

Gratwohl

Baldomero

Frauendorfer

et al. 2008

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Differences in the number of hematopoietic SCTs (HSCT), in transplant rates, in indications and in techniques between countries have been reported. They were attributed mainly to differences in the economic situation of the countries or to differences in prevalences of the disease. On the basis of the results of the annual activity survey on HSCT of the European Blood and Marrow Transplantation (EBMT), we have analyzed the factors associated with differences between more than 600 teams participating from more than 40 countries over a time span of 15 years. The results show a more complex situation. The gross national income per capita, number of transplant teams per 10 million inhabitants or per 10 000 km 2 , team size and team experience all impact on transplant activity. Furthermore, hitherto unknown factors must add to the decisions to perform or not to perform HSCT. These data illustrate that more research is needed to understand the mechanism of HSCT activity and to enable health-care agencies to provide the necessary infrastructure.

show abstract

Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003

Cited by 88 publications

References 37 publications

EBMT activity survey 2004 and changes in disease indication over the past 15 years

EBMT activity survey 2004 and changes in disease indication over the past 15 years

Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs

Why are there regional differences in stem cell transplantation activity? An EBMT analysis

Contact Info

Product

Resources

About